ZA200110168B - Manufacturing method for intravenous immune globulin and resultant product. - Google Patents
Manufacturing method for intravenous immune globulin and resultant product. Download PDFInfo
- Publication number
- ZA200110168B ZA200110168B ZA200110168A ZA200110168A ZA200110168B ZA 200110168 B ZA200110168 B ZA 200110168B ZA 200110168 A ZA200110168 A ZA 200110168A ZA 200110168 A ZA200110168 A ZA 200110168A ZA 200110168 B ZA200110168 B ZA 200110168B
- Authority
- ZA
- South Africa
- Prior art keywords
- solution
- gamma globulin
- globulin solution
- fraction
- detergent
- Prior art date
Links
- 108060003951 Immunoglobulin Proteins 0.000 title description 20
- 102000018358 immunoglobulin Human genes 0.000 title description 20
- 238000004519 manufacturing process Methods 0.000 title description 9
- 238000001990 intravenous administration Methods 0.000 title description 4
- 238000000034 method Methods 0.000 claims description 45
- 239000003599 detergent Substances 0.000 claims description 37
- 239000002202 Polyethylene glycol Substances 0.000 claims description 31
- 229920001223 polyethylene glycol Polymers 0.000 claims description 31
- 102000004169 proteins and genes Human genes 0.000 claims description 31
- 108090000623 proteins and genes Proteins 0.000 claims description 31
- 239000002904 solvent Substances 0.000 claims description 31
- 238000005194 fractionation Methods 0.000 claims description 22
- 108010074605 gamma-Globulins Proteins 0.000 claims description 19
- 238000011282 treatment Methods 0.000 claims description 18
- 238000010438 heat treatment Methods 0.000 claims description 17
- 229910019142 PO4 Inorganic materials 0.000 claims description 14
- 108010032597 Cohn fraction II Proteins 0.000 claims description 13
- 241000700605 Viruses Species 0.000 claims description 13
- 239000010452 phosphate Substances 0.000 claims description 12
- 239000011347 resin Substances 0.000 claims description 12
- 229920005989 resin Polymers 0.000 claims description 12
- 125000002091 cationic group Chemical group 0.000 claims description 11
- 238000000746 purification Methods 0.000 claims description 10
- 238000011084 recovery Methods 0.000 claims description 8
- 239000000440 bentonite Substances 0.000 claims description 7
- 229910000278 bentonite Inorganic materials 0.000 claims description 7
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 claims description 7
- 102000006395 Globulins Human genes 0.000 claims description 6
- 108010044091 Globulins Proteins 0.000 claims description 6
- 238000009295 crossflow filtration Methods 0.000 claims description 5
- STCOOQWBFONSKY-UHFFFAOYSA-N tributyl phosphate Chemical group CCCCOP(=O)(OCCCC)OCCCC STCOOQWBFONSKY-UHFFFAOYSA-N 0.000 claims description 5
- -1 alkyl phosphate Chemical compound 0.000 claims description 4
- 239000003957 anion exchange resin Substances 0.000 claims description 3
- 238000010924 continuous production Methods 0.000 claims description 3
- 239000012535 impurity Substances 0.000 claims description 3
- 230000000415 inactivating effect Effects 0.000 claims description 3
- 238000001556 precipitation Methods 0.000 claims description 2
- 239000003960 organic solvent Substances 0.000 claims 3
- 108010035369 Cohn fraction I Proteins 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 238000005352 clarification Methods 0.000 claims 1
- 239000000243 solution Substances 0.000 description 47
- 230000003612 virological effect Effects 0.000 description 22
- 230000002779 inactivation Effects 0.000 description 21
- 239000000203 mixture Substances 0.000 description 18
- 239000007858 starting material Substances 0.000 description 14
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 12
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 12
- 235000021317 phosphate Nutrition 0.000 description 12
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 11
- 229960002920 sorbitol Drugs 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- 239000000706 filtrate Substances 0.000 description 10
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 229920005654 Sephadex Polymers 0.000 description 9
- 239000012507 Sephadex™ Substances 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 238000001914 filtration Methods 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 239000000600 sorbitol Substances 0.000 description 8
- 239000012760 heat stabilizer Substances 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 239000000539 dimer Substances 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 239000000178 monomer Substances 0.000 description 5
- 239000002244 precipitate Substances 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 108010088751 Albumins Proteins 0.000 description 4
- 102000009027 Albumins Human genes 0.000 description 4
- MZVQCMJNVPIDEA-UHFFFAOYSA-N [CH2]CN(CC)CC Chemical group [CH2]CN(CC)CC MZVQCMJNVPIDEA-UHFFFAOYSA-N 0.000 description 4
- 125000000129 anionic group Chemical group 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 101150026046 iga gene Proteins 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 230000001954 sterilising effect Effects 0.000 description 4
- 238000004659 sterilization and disinfection Methods 0.000 description 4
- 238000000108 ultra-filtration Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 108010071241 Factor XIIa Proteins 0.000 description 3
- 108010088842 Fibrinolysin Proteins 0.000 description 3
- 102000013566 Plasminogen Human genes 0.000 description 3
- 108010051456 Plasminogen Proteins 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 229940012957 plasmin Drugs 0.000 description 3
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 3
- 229920000053 polysorbate 80 Polymers 0.000 description 3
- 239000012460 protein solution Substances 0.000 description 3
- 239000001488 sodium phosphate Substances 0.000 description 3
- 150000005846 sugar alcohols Chemical class 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 229920002684 Sepharose Polymers 0.000 description 2
- 239000008351 acetate buffer Substances 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 150000001450 anions Chemical class 0.000 description 2
- 230000003171 anti-complementary effect Effects 0.000 description 2
- 239000012736 aqueous medium Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 238000010960 commercial process Methods 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 239000002198 insoluble material Substances 0.000 description 2
- 238000004255 ion exchange chromatography Methods 0.000 description 2
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 2
- 229940068968 polysorbate 80 Drugs 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 229910000162 sodium phosphate Inorganic materials 0.000 description 2
- 235000011008 sodium phosphates Nutrition 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 102100022641 Coagulation factor IX Human genes 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 108010076282 Factor IX Proteins 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 108060005987 Kallikrein Proteins 0.000 description 1
- 102000001399 Kallikrein Human genes 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 108090000113 Plasma Kallikrein Proteins 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229920002562 Polyethylene Glycol 3350 Polymers 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- GTVWRXDRKAHEAD-UHFFFAOYSA-N Tris(2-ethylhexyl) phosphate Chemical compound CCCCC(CC)COP(=O)(OCC(CC)CCCC)OCC(CC)CCCC GTVWRXDRKAHEAD-UHFFFAOYSA-N 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000011026 diafiltration Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229960004222 factor ix Drugs 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 229940099472 immunoglobulin a Drugs 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000013618 particulate matter Substances 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 108010058237 plasma protein fraction Proteins 0.000 description 1
- 229940081857 plasma protein fraction Drugs 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229940068977 polysorbate 20 Drugs 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 229940124272 protein stabilizer Drugs 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 125000000185 sucrose group Chemical group 0.000 description 1
- BGRJTUBHPOOWDU-UHFFFAOYSA-N sulpiride Chemical compound CCN1CCCC1CNC(=O)C1=CC(S(N)(=O)=O)=CC=C1OC BGRJTUBHPOOWDU-UHFFFAOYSA-N 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- SFENPMLASUEABX-UHFFFAOYSA-N trihexyl phosphate Chemical compound CCCCCCOP(=O)(OCCCCCC)OCCCCCC SFENPMLASUEABX-UHFFFAOYSA-N 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
- C07K16/065—Purification, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US33328999A | 1999-06-15 | 1999-06-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200110168B true ZA200110168B (en) | 2002-08-26 |
Family
ID=23302162
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200110168A ZA200110168B (en) | 1999-06-15 | 2001-12-11 | Manufacturing method for intravenous immune globulin and resultant product. |
Country Status (13)
Country | Link |
---|---|
EP (1) | EP1185290A4 (cs) |
JP (1) | JP2003501480A (cs) |
KR (1) | KR20020010921A (cs) |
CN (1) | CN1358100A (cs) |
AU (1) | AU756071B2 (cs) |
BR (1) | BR0011648A (cs) |
CA (1) | CA2375560A1 (cs) |
CZ (1) | CZ20014456A3 (cs) |
HK (1) | HK1048252A1 (cs) |
IL (1) | IL146433A0 (cs) |
PL (1) | PL352910A1 (cs) |
WO (1) | WO2000076534A1 (cs) |
ZA (1) | ZA200110168B (cs) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2437518A (en) * | 2006-04-26 | 2007-10-31 | Noel Kavanagh | Antiserum preparation |
WO2007136327A1 (en) * | 2006-05-22 | 2007-11-29 | Ge Healthcare Bio-Sciences Ab | A method of producing igg |
US7932356B1 (en) * | 2010-06-23 | 2011-04-26 | Bing Lou Wong | Method for the preparation of a heat stable oxygen carrier-containing pharmaceutical composition |
ES2785375T3 (es) | 2014-03-11 | 2020-10-06 | Green Cross Holdings Corp | Procedimiento de purificación de inmunoglobulina |
CA2941232C (en) * | 2014-03-11 | 2020-08-25 | Green Cross Holdings Corporation | Method for purifying immunoglobulin |
KR101941974B1 (ko) * | 2016-11-18 | 2019-01-24 | 주식회사 녹십자 | 혈장 단백질 정제시 fxi의 제거방법 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4820805A (en) * | 1983-07-14 | 1989-04-11 | New York Blood Center, Inc. | Undenatured virus-free trialkyl phosphate treated biologically active protein derivatives |
FR2582515B1 (fr) * | 1985-05-30 | 1988-11-04 | Merieux Inst | Procede de preparation de gamma-gobulines administrables par voie intraveineuse et gamma-globulines obtenues |
JPH0662436B2 (ja) * | 1986-05-19 | 1994-08-17 | 株式会社ミドリ十字 | 静注用免疫グロブリン製剤の製造方法 |
US4841023A (en) * | 1986-06-25 | 1989-06-20 | New York Blood Center, Inc. | Inactivation of viruses in labile protein-containing compositions using fatty acids |
DE69011136T3 (de) * | 1989-01-13 | 2003-10-23 | Mitsubishi Pharma Corp | Verfahren zur Herstellung einer Protein enthaltenden Zusammensetzung. |
DE3927111C3 (de) * | 1989-08-17 | 1994-09-01 | Biotest Pharma Gmbh | Verfahren zur Herstellung nicht modifizierter intravenös verabreichbarer IgM- und/oderIgA-haltiger Immunglobulinpräparate |
JP3145696B2 (ja) * | 1990-10-05 | 2001-03-12 | 日本ケミカルリサーチ株式会社 | 分泌型免疫グロブリンa製剤の製造法 |
US5110910A (en) * | 1991-03-25 | 1992-05-05 | Miles Inc. | Virucidal euglobulin precipitation |
DE4431833C1 (de) * | 1994-09-07 | 1995-05-18 | Blutspendedienst Der Drk Lande | Verfahren zur Herstellung eines AHF-Konzentrates |
UA64742C2 (uk) * | 1997-12-24 | 2004-03-15 | Альфа Терапевтик Корпорейшн | СПОСІБ ОДЕРЖАННЯ РОЗЧИНУ <font face="Symbol">g</font>-ГЛОБУЛІНУ, ПРИЗНАЧЕНОГО ДЛЯ ВНУТРІШНЬОВЕННОГО ВВЕДЕННЯ, І ПРОДУКТ, ЩО ОДЕРЖУЄТЬСЯ У ЦЕЙ СПОСІБ (ВАРІАНТИ) |
-
2000
- 2000-06-06 WO PCT/US2000/011870 patent/WO2000076534A1/en not_active Application Discontinuation
- 2000-06-06 CZ CZ20014456A patent/CZ20014456A3/cs unknown
- 2000-06-06 IL IL14643300A patent/IL146433A0/xx unknown
- 2000-06-06 BR BR0011648-3A patent/BR0011648A/pt not_active Application Discontinuation
- 2000-06-06 AU AU57224/00A patent/AU756071B2/en not_active Expired
- 2000-06-06 CA CA002375560A patent/CA2375560A1/en not_active Abandoned
- 2000-06-06 PL PL00352910A patent/PL352910A1/xx not_active Application Discontinuation
- 2000-06-06 EP EP00942627A patent/EP1185290A4/en not_active Withdrawn
- 2000-06-06 KR KR1020017015561A patent/KR20020010921A/ko not_active Application Discontinuation
- 2000-06-06 JP JP2001502867A patent/JP2003501480A/ja active Pending
- 2000-06-06 CN CN00808372A patent/CN1358100A/zh active Pending
-
2001
- 2001-12-11 ZA ZA200110168A patent/ZA200110168B/en unknown
-
2003
- 2003-01-09 HK HK03100222.7A patent/HK1048252A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
WO2000076534A1 (en) | 2000-12-21 |
IL146433A0 (en) | 2002-07-25 |
HK1048252A1 (zh) | 2003-03-28 |
AU756071B2 (en) | 2003-01-02 |
CA2375560A1 (en) | 2000-12-21 |
PL352910A1 (en) | 2003-09-22 |
CZ20014456A3 (cs) | 2002-05-15 |
AU5722400A (en) | 2001-01-02 |
KR20020010921A (ko) | 2002-02-06 |
EP1185290A1 (en) | 2002-03-13 |
JP2003501480A (ja) | 2003-01-14 |
CN1358100A (zh) | 2002-07-10 |
EP1185290A4 (en) | 2005-08-31 |
BR0011648A (pt) | 2002-03-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5042817B2 (ja) | ウイルス安全精製抗体調製物を提供する方法 | |
KR20070009995A (ko) | 바이러스 안전성 면역글로불린을 제조하는 방법 | |
EP1041998A1 (en) | Composition and method for dermal and transdermal administration of a cytokine | |
AU2013203112B2 (en) | Fraction I-IV-1 Precipitation of immunoglobins from plasma | |
US6162904A (en) | Manufacturing method for intraveneously administrable immune globulin and resultant product | |
US20060177909A1 (en) | Preparation of immunoglobulin | |
AU747893B2 (en) | Production process for intravenous immune serum globulin and resultant product | |
US6504012B2 (en) | Method for preparing dual virally inactivated immune globulin for intravenous administration | |
JP2018528249A (ja) | ヒト血漿由来b型肝炎免疫グロブリン製剤の製造方法 | |
AU756071B2 (en) | Manufacturing method for intravenous immune globulin and resultant product | |
JP2008094722A (ja) | 免疫グロブリン製剤の製造方法 | |
MXPA99007835A (en) | Production process for intravenous immune serum globulin and resultant product | |
JP2023519956A (ja) | C-1インヒビター欠乏血漿から免疫グロブリン製剤を生産する方法 | |
CZ293499A3 (cs) | Způsob přípravy intravenózně aplikovatelného roztoku gammaglobulinu a výsledný produkt |